Bezlotoxumab denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for bezlotoxumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Bezlotoxumab as Experimental

An experimental or investigational denial signals that Aetna's reviewer applied a coverage policy classifying bezlotoxumab as lacking sufficient evidence of clinical benefit for the specific indication or patient profile described in the claim. This denial reason is particularly surprising for bezlotoxumab because it holds full FDA approval for reducing recurrence of Clostridioides difficile infection in adults receiving antibacterial treatment. An experimental denial for an FDA-approved drug in its approved indication is a strong candidate for appeal.

## Why This Denial Is Appealable

FDA approval is the threshold marker distinguishing approved from experimental treatments under most insurer coverage frameworks. If bezlotoxumab was prescribed and billed for its FDA-approved indication, Aetna's experimental classification directly conflicts with the drug's regulatory status. Professional society guidelines from organizations such as the Infectious Diseases Society of America (IDSA) address the role of bezlotoxumab in C. difficile management. Your appeal should anchor on the FDA label, the IDSA guidance, and the prescriber's statement that use is within the approved indication.

## Federal Appeal Framework

• Internal appeal: ERISA §503 requires a full-and-fair review. Deadlines vary; act promptly on receiving the denial.
• External review (ACA §2719): After the final internal denial, an Independent Review Organization can review whether the experimental classification is supported. The general window is approximately four months from the final internal denial.
• Expedited review: Available when standard timelines would seriously jeopardize health. Request in writing with prescriber certification.

## Concrete Appeal Steps

1. Obtain Aetna's exact coverage policy language — specifically the criteria used to classify bezlotoxumab as experimental. 2. Download the current FDA-approved prescribing label (Zinplava) and identify the approved indication verbatim. 3. Confirm the prescribed use matches the approved indication exactly. 4. Ask your prescriber to provide a letter citing the FDA-approved status and any applicable published IDSA guidance. 5. File the internal appeal in writing, attaching all supporting documents.

## Documentation to Gather

• Diagnosis confirmation: Laboratory-confirmed C. difficile infection documentation.
• Prior recurrence history: Dates and outcomes of any prior C. difficile episodes.
• FDA label: Printed copy of the current Zinplava prescribing information, highlighting indication text.
• IDSA guidance reference: Ask your prescriber to cite the applicable guideline version without relying on specific statistics.
• Prescriber medical-necessity letter: Attesting that use is within the FDA-approved indication and is consistent with current infectious disease specialty standards.

## Criteria-Mapping Structure

Review Aetna's experimental/investigational coverage policy and identify every evidentiary criterion the plan applies. For each criterion, provide a direct response: the FDA label text showing approval, the published guideline organization's position (cited by name and version, not statistics), and your prescriber's clinical rationale. If Aetna's policy cites specific evidence tiers, ask your prescriber whether peer-reviewed literature exists that addresses those tiers and have them summarize it in lay terms in the letter. A complete point-by-point rebuttal aligned to Aetna's own policy criteria is the most effective format for this denial type.